他克莫司与来氟米特治疗特发性膜性肾病的效果及安全性对比

Abstract
Figure/Table
References (16)
Related Citation (13)

Download: PDF (0 KB) HTML (27 KB)
Export: BibTeX | EndNote (RIS)

Abstract ObjectiveTo compare the efficacy and safety of tacrolimus and leflunomide in the treatment of idiopathic membranous nephropathy.Methods80 patients with membranous nephropathy treated in our hospital from June 2015 to January 2017 were selected as the subjects,and divided into control group and observation group according to random data table method,40 cases in each group.All patients were treated with prednisone regularly.In addition,patients in the control group were treated with leflunomide,and patients in the observation group were treated with tacrolimus,6 months for a course of treatment.The difference of clinical efficacy between the two groups was compared.ResultsAfter treatment,the renal function indexes such as 24 h urinary protein and serum creatinine in the observation group were lower than those in the control group,the difference was statistically significant(P＜0.05).Triglyceride (TG),total cholesterol(TC)and other blood lipid levels in the observation group were lower than those in the control group,the difference was statistically significant(P＜0.05).The total effective rate of the observation group (77.50%)was higher than that of the control group (55.00%),the difference was statistically significant(P＜0.05).The total incidence of adverse reactions in the observation group(30.00%)was higher than that of the control group(13.33%),the difference was statistically significant (P＜0.05).ConclusionFor leflunomide,tacrolimus is more effective in the treatment of idiopathic membranous nephropathy.Tacrolimus can effectively improve renal function and blood lipid levels,safe and reliable,which is worthy of promotion.

Key words： Tacrolimus Leflunomide Idiopathic membranous nephropathy Safety Renal function

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Tian-qi
	YANG Ying-da

Cite this article:

WANG Tian-qi,YANG Ying-da. Comparison of efficacy and safety between tacrolimus and leflunomide in the treatment of idiopathic membranous nephropathy[J]. 中国当代医药, 2018, 25(2): 138-140转144.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2018/V25/I2/138

[1]	张洋，孙晶，宋艳艳.他克莫司联合小剂量泼尼松治疗Ⅰ、Ⅱ期膜性肾病[J].贵阳医学院学报，2011，36（6）：576-578.
[2]	刘书真.环磷酰胺、来氟米特联合泼尼松序贯疗法用于Ⅱ期膜性肾病的临床观察[J].中国药房，2016，27（15）：2040-2042.
[3]	刘沫轩.泼尼松联合环磷酰胺治疗肾病综合征并肾功能不全 41 例疗效及安全性评价[J].中国药业，2014，23（17）：20-21.
[4]	周晓云，周杨.他克莫司单药治疗特发性膜性肾病的近期疗效[J].中国中西医结合肾病杂志，2014，15（8）：706-708.
[5]	黎磊石，刘志红.中国肾脏病学[M].北京：人民军医出版社，2008：640-645.
[6]	陈超阳，盛晓燕，周颖，等.他克莫司治疗原发性肾病综合征的疗效和安全性的Meta分析[J].中国新药杂志，2015，24（1）：64-73.
[7]	江罗佳，冯益宇，房向东，等.他克莫司与环磷酰胺比较治疗特发性膜性肾病的系统评价[J].实用医学杂志，2014，30（1）：121-126.
[8]	段玉静，柴华旗，沙文刚，等.75例特发性膜性肾病临床病理分析[J].安徽医药，2014，18（8）：1530-1532.
[9]	章友康.特发性膜性肾病的诊断治疗进展[J].内科急危重症杂志，2012，18（2）：118-119.
[10]	李艺，王帅，赵景宏，等.他克莫司与环磷酰胺联合激素治疗特发性膜性肾病的疗效比较[J].中国临床药理学与治疗学，2012，17（7）：797-801.
[11]	李超，管音，李航，等.特发性膜性肾病诊断与治疗的新认识[J].临床内科杂志，2014，31（5）：293-296.
[12]	刘国建，鲍运霞，张威，等.他克莫司联合糖皮质激素治疗特发性膜性肾病的临床观察[J].哈尔滨医科大学学报，2015，49（5）：446-449.
[13]	黄远航，范立明，胡静，等.半量激素联合他克莫司治疗特发性膜性肾病的临床研究[J].中国药房，2013，24（14）：1297-1299.
[14]	陈意志，李平，胡婕，等.新型免疫抑制剂治疗特发性膜性肾病的Meta分析[J].中华肾病研究电子杂志，2014，3（2）：91-98.
[15]	侯终君.他克莫司联合糖皮质激素治疗特发性膜性肾病的临床效果[J].中国医药导报，2014，11（31）：69-72.
[16]	常雄.他克莫司或来氟米特联合泼尼松治疗特发性膜性肾病的疗效及安全性对比[J].药物评价研究，2016，39（5）：818-820.